Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 58
Filter
1.
Bone Marrow Transplant ; 47(7): 946-51, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22056644

ABSTRACT

The purpose of the study was to determine the long-term safety and effectiveness of high-dose immunosuppressive therapy (HDIT) followed by autologous hematopoietic cell transplantation (AHCT) in advanced multiple sclerosis (MS). TBI, CY and antithymocyte globulin were followed by transplantation of autologous, CD34-selected PBSCs. Neurological examinations, brain magnetic resonance imaging and cerebrospinal fluid (CSF) for oligoclonal bands (OCB) were serially evaluated. Patients (n=26, mean Expanded Disability Status Scale (EDSS)=7.0, 17 secondary progressive, 8 primary progressive, 1 relapsing/remitting) were followed for a median of 48 months after HDIT followed by AHCT. The 72-month probability of worsening ≥1.0 EDSS point was 0.52 (95% confidence interval, 0.30-0.75). Five patients had an EDSS at baseline of ≤6.0; four of them had not failed treatment at last study visit. OCB in CSF persisted with minor changes in the banding pattern. Four new or enhancing lesions were seen on MRI, all within 13 months of treatment. In this population with high baseline EDSS, a significant proportion of patients with advanced MS remained stable for as long as 7 years after transplant. Non-inflammatory events may have contributed to neurological worsening after treatment. HDIT/AHCT may be more effective in patients with less advanced relapsing/remitting MS.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Immunosuppression Therapy/methods , Multiple Sclerosis/therapy , Adult , Antilymphocyte Serum/therapeutic use , Female , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Multiple Sclerosis/drug therapy , Multiple Sclerosis/pathology , Multiple Sclerosis/surgery , Transplantation, Autologous , Treatment Outcome , Whole-Body Irradiation
2.
Bone Marrow Transplant ; 41(9): 791-5, 2008 May.
Article in English | MEDLINE | ID: mdl-18246118

ABSTRACT

We reviewed records of hematopoietic cell transplantation (HCT) patients seen over the past 10 years who had head scan documentation of subdural fluid collections. A total of 17 patients were identified: 13 with allogeneic and 4 with autologous HCT (0.71% of allogeneic and 0.13% of autologous HCT patients seen in this time interval). Although less than 20% of HCT patients have lumbar puncture, 8 of the 17 subdural patients had lumbar puncture. The lumbar puncture was done 5-112 days (median 46 days) before subdural detection. Acute lymphocytic leukemia was the diagnosis in five of these eight; whereas, either acute myelogenous leukemia or myelodysplasia was the diagnosis in seven of the nine patients without lumbar puncture. In the patient group with lumbar puncture, subdurals were diagnosed earlier after HCT (median 25 days versus 5 months in the patient group without lumbar puncture) and were more often hygromas (37.5 versus 0%). These results support the suggestion of lumbar puncture or intrathecal therapy as a risk factor for subdurals. The presumptive mechanism involves lumbar cerebrospinal leak, low intracranial pressure, downward displacement of the brain, cerebrospinal fluid accumulation into the inner dural layers of the cerebral convexities (hygromas) and bleeding into these fluid collections (hematomas).


Subject(s)
Hematologic Neoplasms/therapy , Hematoma, Subdural, Spinal , Hematopoietic Stem Cell Transplantation , Spinal Puncture/adverse effects , Subdural Effusion , Adolescent , Adult , Aged , Female , Humans , Injections, Spinal/adverse effects , Male , Middle Aged , Retrospective Studies , Risk Factors , Time Factors , Transplantation, Autologous , Transplantation, Homologous
3.
Mult Scler ; 12(6): 814-23, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17263012

ABSTRACT

Over the last decade, hematopoietic stem cells transplantation (HSCT) has been increasingly used in the treatment of severe progressive autoimmune diseases. We report a retrospective survey of 183 multiple sclerosis (MS) patients, recorded in the database of the European Blood and Marrow Transplantation Group (EBMT). Transplant data were available from 178 patients who received an autologous graft. Overall, transplant related mortality (TRM) was 5.3% and was restricted to the period 1995-2000, with no further TRM reported since then. Busulphan-based regimens were significantly associated with TRM. Clinical status at the time of transplant and transplant techniques showed some correlations with toxicity. No toxic deaths were reported among the 53 patients treated with the BEAM (carmustine, etoposide, cytosine-arabinoside, melphalan)/antithymocyte globulin (ATG) regimen without graft manipulation, irrespective of their clinical condition at the time of the transplant. Improvement or stabilization of neurological conditions occurred in 63% of patients at a median follow-up of 41.7 months, and was not associated with the intensity of the conditioning regimen. In this large series, HSCT was shown as a promising procedure to slow down progression in a subset of patients affected by severe, progressive MS; the safety and feasibility of the procedure can be significantly improved by appropriate patient selection and choice of transplant regimen.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/mortality , Multiple Sclerosis, Chronic Progressive/mortality , Multiple Sclerosis, Chronic Progressive/therapy , Adolescent , Adult , Databases, Factual , Disability Evaluation , Disease Progression , Europe , Female , Follow-Up Studies , Hematopoietic Stem Cell Mobilization/adverse effects , Hematopoietic Stem Cell Mobilization/mortality , Humans , Male , Middle Aged , Multiple Sclerosis, Chronic Progressive/physiopathology , Registries , Retrospective Studies , Survival Analysis , Transplantation, Autologous
4.
Mult Scler ; 12(6): 824-5, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17263013

ABSTRACT

At a conference held in October 2005, participants presented studies on high dose immunosuppression with hematopoietic cell transplant (HCT) for multiple sclerosis (MS), including neuroimmunological and magnetic resonance imaging (MRI) mechanistic approaches, clinical registry reports, and ongoing or newly-designed protocols. A discussion panel considered questions on how to define success, timing of controlled clinical trials, difficulty in patient recruitment, and future direction of high dose therapy.


Subject(s)
Hematopoietic Stem Cell Transplantation/trends , Immunosuppression Therapy/trends , Multiple Sclerosis/therapy , Humans , Magnetic Resonance Imaging , Multiple Sclerosis/pathology , Registries
6.
J Neurol ; 249(8): 1088-97, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12195460

ABSTRACT

RATIONALE: Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis ( MS) were initiated, based on results of experimental transplantation in animal models of multiple sclerosis and clinical observations in patients treated concomitantly for malignant disease. PATIENTS: Eighty-five patients with progressive MS were treated with autologous HSCT in 20 centers and reported to the autoimmune disease working party of the European Group for Blood and Marrow Transplantation (EBMT). 52 (61 %) were female, median age was 39 [20-58] years. The median interval from diagnosis to transplant was 7 [1-26] years. Patients suffered from severe disease with a median EDSS score of 6.5 [4.5-8.5]. Active disease prior to transplant was documented in 79 of 82 evaluable cases. RESULTS: The stem cell source was bone marrow in 6 and peripheral blood in 79, and stem cells were mobilized into peripheral blood using either cyclophosphamide combined with growth factors or growth factors alone. Three patients experienced transient neurological complications during the mobilization phase. The high dose regimen included combination chemotherapy, with or without anti-lymphocyte antibodies or, with or without, total body irradiation. The stem cell transplants were purged of lymphocytes in 52 patients. Median follow-up was 16 [3-59] months. There were 7 deaths, 5 due to toxicity and infectious complications, 2 with neurological deterioration. The risk of death of any cause at 3 years was 10 (+/-7)% (95 % confidence interval). Neurological deterioration during transplant was observed in 22 patients; this was transient in most but was associated with MS progression in 6 patients. Neurological improvement by > or = 1 point in the EDSS score was seen in 18 (21 %) patients. Confirmed progression-free survival was 74 (+/-12)% at 3 years being 66 (+/-23)% in patients with primary progressive MS but higher in patients with secondary progressive or relapsing-remitting MS, 78 (+/-13)%; p = 0.59. The probability of confirmed disease progression was 20 (+/-11)%. MRI data were available in 78 patients before transplant showing disease activity (gadolinium enhancing, new or enlarging lesions) in 33 %. Posttransplant MRI showed activity at any time in 5/61 (8 %) evaluable cases. CONCLUSION: Autologous HSCT suggest positive early results in the management of progressive MS and is feasible. These multicentre data suggest an association with significant mortality risks especially in some patient groups and are being utilised in the planning of future trials to reduce transplant related mortality.


Subject(s)
Hematopoietic Stem Cell Transplantation , Multiple Sclerosis, Chronic Progressive/therapy , Transplantation Conditioning , Adult , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/mortality , CD4 Lymphocyte Count , Disease Progression , Disease-Free Survival , Female , Hematopoietic Stem Cell Mobilization/adverse effects , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/mortality , Humans , Male , Middle Aged , Multiple Sclerosis, Chronic Progressive/immunology , Multiple Sclerosis, Chronic Progressive/mortality , Retrospective Studies , Transplantation Conditioning/adverse effects , Treatment Outcome
8.
J Virol ; 75(6): 3048-52, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11222734

ABSTRACT

Gender influences the incidence and severity of some bacterial and viral infections and autoimmune diseases in animal models and humans. To determine a gender-based difference, comparisons were made between male and female mice inoculated with herpes simplex virus type 1 (HSV-1) by the corneal route. Mortality was higher in the male mice of the three strains tested: 129/Sv//Ev wild type, gamma interferon (IFN-gamma) knockout (GKO), and IFN-gamma receptor knockout (RGKO). Similarly, in vivo HSV-1 reactivation occurred more commonly in male mice, but the male-female difference in reactivation was restricted to the two knockout strains and was not seen in the 129/Sv//Ev control. Comparison among male mice of the three strains showed a higher mortality of the RGKO mice and a higher reactivation rate of the GKO and RGKO mice than of the 129/Sv//Ev males. In contrast, female RGKO and GKO mice did not differ from female 129/Sv//Ev controls in either mortality or reactivation. HSV-1 periocular and eyelid disease was also more severe in male and dihydrotestosterone (DHT)-treated female mice than in control female mice. These results show a consistent gender difference in HSV-1 infection, with a worse outcome in male mice. In addition, the results comparing GKO and RGKO mice to controls show differences only in male mice, suggesting that some effects of IFN-gamma, a key immunoregulatory molecule, are gender specific.


Subject(s)
Herpes Simplex/immunology , Herpes Simplex/virology , Herpesvirus 1, Human/physiology , Interferon-gamma/immunology , Sex Characteristics , Acute Disease , Animals , Disease Susceptibility , Female , Interferon-gamma/genetics , Keratitis, Herpetic/immunology , Keratitis, Herpetic/virology , Male , Mice , Mutation , Testosterone/pharmacology , Virus Activation , Virus Latency
9.
Biol Blood Marrow Transplant ; 6(5A): 563-75, 2000.
Article in English | MEDLINE | ID: mdl-11071262

ABSTRACT

Multiple sclerosis (MS) is an immune-mediated disease that may be amenable to high-dose immunosuppression with peripheral blood stem cell transplantation (SCT) in selected patients. Five MS patients (all women, ages 39-47 years) received granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization, CD34 cell selection for T-cell depletion, a preparatory regimen of busulfan (1 mg/kg x 16 doses) and cyclophosphamide (120 mg/kg), and antithymocyte globulin (10 mg/kg x 3 doses) at the time of stem cell infusion. Days required to recover absolute neutrophil count >500 were 12 to 14 and platelet count >20,000 were 17 to 58. Posttransplantation infectious complications in the first year after SCT occurred in 3 of 5 patients, and 1 patient died at day 22 after SCT from influenza A pneumonia. Neuropathologic study in this patient showed demyelinating plaques with surrounding macrophages but only rare T cells. In 2 patients, MS flared transiently with G-CSF. Magnetic resonance imaging gadolinium enhancement was present in 3 of 5 patients before transplantation and 0 of 4 after SCT. There were cerebrospinal fluid oligoclonal bands at 1 year after SCT, similar to the pretransplantation assays. Sustained suppression of peripheral blood mononuclear cell proliferative responses to myelin antigens occurred after SCT, but new responses to some myelin peptide fragments also developed after SCT. In 1 patient, enzyme-linked immunospot (ELISPOT) assays done 9 months after SCT showed a predominant T helper 2 (Th2) cytokine pattern. Neurological progression of 1 point on the extended disability status scale was seen in 1 patient 17 months after SCT. Another patient who was neurologically stable died abruptly 19 months after SCT from overwhelming S. pneumoniae sepsis. The remaining patients have had stable MS (follow-up, 18 and 30 months). In summary, our experience confirms the high-risk nature of this approach. Further studies and longer follow-up would be needed to determine the significance of new lymphocyte proliferative responses after SCT and the overall effect of this treatment on the natural history of MS.


Subject(s)
Autoimmune Diseases/therapy , Busulfan/administration & dosage , Cyclophosphamide/administration & dosage , Hematopoietic Stem Cell Transplantation , Multiple Sclerosis/therapy , Transplantation Conditioning , Adult , Autoantibodies/immunology , Autoantigens/immunology , Autoimmune Diseases/cerebrospinal fluid , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , Brain/pathology , Busulfan/adverse effects , Cells, Cultured , Combined Modality Therapy , Cyclophosphamide/adverse effects , Cytotoxicity, Immunologic , Disease Progression , Female , Granulocyte Colony-Stimulating Factor/adverse effects , Granulocyte Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cell Mobilization , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Immunodominant Epitopes/immunology , Immunosuppression Therapy , Immunosuppressive Agents/therapeutic use , Infections/etiology , Infections/mortality , Lymphocyte Activation , Magnetic Resonance Imaging , Methylprednisolone/therapeutic use , Middle Aged , Multiple Sclerosis/cerebrospinal fluid , Multiple Sclerosis/immunology , Multiple Sclerosis/pathology , Myelin Sheath/immunology , T-Lymphocyte Subsets/immunology , Transplantation Conditioning/adverse effects , Treatment Outcome
10.
Neurology ; 54(11): 2147-50, 2000 Jun 13.
Article in English | MEDLINE | ID: mdl-10851379

ABSTRACT

Four of 10 patients who were enrolled on protocols of high-dose immunosuppression with peripheral blood stem cell rescue for MS experienced neurologic worsening while receiving recombinant human granulocyte colony-stimulating factor. There was improvement when methylprednisolone was given to three of the patients, but one patient died of respiratory failure. The mechanism of the neurologic worsening is uncertain.


Subject(s)
Granulocyte Colony-Stimulating Factor/adverse effects , Multiple Sclerosis/drug therapy , Adult , Anti-Inflammatory Agents/therapeutic use , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Male , Methylprednisolone/therapeutic use , Middle Aged , Paralysis/chemically induced , Paralysis/drug therapy , Recombinant Proteins
11.
J Virol ; 73(6): 5196-200, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10233988

ABSTRACT

Mouse strains with null mutations in the gamma interferon gene (Ifng) or the gamma interferon receptor gene (Ifngr) have been engineered. The use of these strains as animal models of viral and bacterial infections has enhanced our understanding of the role of gamma interferon (IFN-gamma) in the host immune response. However, direct comparisons between Ifng-/- (GKO) and Ifngr-/- (RGKO) mice have been problematic because previously available strains of these mice have had different genetic backgrounds (i.e., C57BL/6 and BALB/c for GKO mice and 129/Sv//Ev for RGKO mice). To enable direct comparison of herpes simplex virus type 1 (HSV-1) infections in GKO and RGKO mice, we introduced the IFN-gamma null mutation into the 129/Sv//Ev background. We report that, after HSV-1 inoculation, mortality was significantly greater in RGKO mice than in GKO mice (38 versus 23%, P = 0.0001). Similarly, the mortality from vaccinia virus challenge was significantly greater in RGKO mice than in GKO mice. With differences in genetic background excluded as a confounding issue, these results are consistent with the existence of an alternative ligand(s) for the IFN-gamma receptor that is also capable of mediating protection against viral challenge.


Subject(s)
Herpes Simplex/immunology , Interferon-gamma/physiology , Receptors, Interferon/physiology , Animals , Disease Susceptibility , Herpes Simplex/mortality , Mice , Mice, Inbred C57BL , Mice, Knockout , Phenotype , Interferon gamma Receptor
12.
J Virol ; 73(4): 3418-23, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10074196

ABSTRACT

Observation of chronic inflammatory cells and associated high-level gamma interferon (IFN-gamma) production in ganglia during herpes simplex type 1 (HSV-1) latent infection in mice (E. M. Cantin, D. R. Hinton, J. Chen, and H. Openshaw, J. Virol. 69:4898-4905, 1995) prompted studies to determine a role of IFN-gamma in maintaining latency. Mice lacking IFN-gamma (GKO mice) or the IFN-gamma receptor (RGKO mice) were inoculated with HSV-1, and the course of the infection was compared with that in IFN-gamma-competent mice with the same genetic background (129/Sv//Ev mice). A time course study showed no significant difference in trigeminal ganglionic viral titers or the timing of establishment of latency. Spontaneous reactivation resulting in infectious virus in the ganglion did not occur during latency in any of the mice. However, 24 h after the application of hyperthermic stress to mice, HSV-1 antigens were detected in multiple neurons in the null mutant mice but in only a single neuron in the 129/Sv//Ev control mice. Mononuclear inflammatory cells clustered tightly around these reactivating neurons, and by 48 h, immunostaining was present in satellite cells as well. The incidence of hyperthermia-induced reactivation as determined by recovery of infectious virus from ganglia was significantly higher in the null mutant than in control mice: 11% in 129/Sv//Ev controls, 50% in GKO mice (P = 0.0002), and 33% in RGKO mice (P = 0.03). We concluded that IFN-gamma is not involved in the induction of reactivation but rather contributes to rapid suppression of HSV once it is reactivated.


Subject(s)
Herpes Simplex/physiopathology , Herpesvirus 1, Human/physiology , Interferon-gamma/physiology , Animals , Herpes Simplex/genetics , Herpes Simplex/pathology , Humans , Immunohistochemistry , Mice , Mutation , Neurons/virology , Virus Activation , Virus Latency
13.
J Neurol Sci ; 154(2): 194-9, 1998 Feb 05.
Article in English | MEDLINE | ID: mdl-9562310

ABSTRACT

We assayed IL-6 in 105 cerebrospinal fluid (CSF) samples from patients with ALS, MS, HTLV-1 associated myelopathy (HAM), and controls. There was considerable overlap in IL-6 levels in all patient groups. The mean IL-6 in 27 patients with ALS was significantly higher than in 21 patients in the other neurological disease (OND) group (P=0.0075). There were no significant differences in MS or HAM and the OND control group. Overall, CSF IL-6 correlated with protein concentration but not with percentage IgG or IgG-albumin index. Patients with CSF oligoclonal bands were no more likely to have detectable IL-6 than patients without oligoclonal bands. Similarly, IL-6 did not correlate with clinical disease activity in MS when subgroups of patients were compared or when an individual patient was followed over time. The elevated IL-6 in ALS may reflect an ongoing humoral immune response, or IL-6 may be non-specifically expressed in these patients as a putative neurotrophic factor in response to nerve cell degeneration.


Subject(s)
Amyotrophic Lateral Sclerosis/cerebrospinal fluid , Central Nervous System Diseases/cerebrospinal fluid , Inflammation/cerebrospinal fluid , Interleukin-6/cerebrospinal fluid , Amyotrophic Lateral Sclerosis/immunology , Central Nervous System Diseases/immunology , Humans , Inflammation/immunology , Logistic Models , Multiple Sclerosis/cerebrospinal fluid , Paraparesis, Tropical Spastic/cerebrospinal fluid
14.
Biol Blood Marrow Transplant ; 3(4): 202-9, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9360782

ABSTRACT

Peripheral neuropathy after bone marrow transplantation can produce motor disability with significant morbidity and mortality, particularly when the neuropathy occurs within the first few months of the transplant. Most of these severe neuropathies have demyelinating features on electrophysiologic tests and histopathology, characteristic of immunologically-mediated neuropathies. The specific immune mechanism is uncertain. It is possible that cyclosporin, FK-506, and interferon-alpha may all trigger immunologically mediated neuropathies in rare patients. Transplants in patients with pre-existing demyelinating neuropathy may result in abrupt exacerbation of the neuropathy. Other causes of severe neuropathies include high-dose cytosine arabinoside and critical illness polyneuropathy. Less severe neuropathies with primarily sensory deficits may result from etoposide conditioning, thalidomide treatment for graft-versus-host disease, and the chemotherapeutic agents cisplatin and paclitaxel when used at high-dose with peripheral stem cell support. When encountering patients with disabling motor neuropathies, transplant physicians must identify (with the aid of nerve conduction tests) those neuropathies that are likely to be immunologically mediated and then empirically add or alter immunosuppressant therapies. Unfortunately, experience has been too limited to suggest specific regimens or the optimal sequence of immunosuppressant therapies.


Subject(s)
Bone Marrow Transplantation/adverse effects , Peripheral Nervous System Diseases/etiology , Bone Marrow Transplantation/mortality , Cyclosporine/adverse effects , Cytarabine/adverse effects , Demyelinating Diseases/complications , Humans , Immunosuppressive Agents/adverse effects , Interferon-alpha/adverse effects , Tacrolimus/adverse effects , Time Factors
15.
Bone Marrow Transplant ; 19(5): 503-5, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9052919

ABSTRACT

After 582 allogeneic bone marrow transplants, we have encountered four patients (0.7%) who developed transient unilateral or bilateral sixth nerve palsies. Three of the four patients also had bilateral ptosis. These signs resolved 24-48 h after cyclosporin and ganciclovir were discontinued. One patient had MRI T2 abnormalities compatible with cyclosporin neurotoxicity. We postulate that cyclosporin, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients.


Subject(s)
Abducens Nerve , Antiviral Agents/adverse effects , Blepharoptosis/chemically induced , Bone Marrow Transplantation , Cyclosporine/adverse effects , Ganciclovir/adverse effects , Immunosuppressive Agents/adverse effects , Ophthalmoplegia/chemically induced , Adolescent , Adult , Cranial Nerve Diseases/chemically induced , Cytomegalovirus Infections/drug therapy , Diplopia/chemically induced , Female , Graft vs Host Disease/prevention & control , Humans , Leukemia/therapy , Male , Viremia/drug therapy
16.
Arch Virol ; 142(4): 721-36, 1997.
Article in English | MEDLINE | ID: mdl-9170500

ABSTRACT

Utilizing co-transfection of DNA from glycoprotein gB- strain of HSV1 and cloned fragments of several simian alpha-herpesviruses containing the UL26, UL27 (gB glycoprotein), and UL28 gene homologs, replication-competent recombinant viruses were produced. Genetic analysis of one HSV1/SA8 recombinant (HSV1/SgB) demonstrated the presence of SA8 DNA comprising the entire UL27 (gB) gene and parts of the UL28 and UL26 ORFs in an otherwise HSV1 genome. The recombinant was shown to express the SA8 gB and p40 proteins (UL27 & UL26.5 gene products, respectively); all other proteins were indistinguishable from those of HSV1. The recombinant behaved like SA8 in gB-specific virus neutralization and cell surface antibody binding assays, while plaque morphology and replication kinetics were very similar to HSV1. Despite its overwhelming HSV1 genetic constitution, the recombinant displayed a pathogenic phenotype in mice very different from the parental HSV1. While HSV1 produced corneal disease in ocularly infected mice and readily spread to the nervous system. HSV1/SgB was markedly impaired in both respects. These results demonstrate the functional equivalency of the cercopithecine monkey virus gB glycoproteins and genes (including transcriptional regulatory elements) in HSV1, the functional nature of HSV1/SA8 chimeric UL28 and UL26 genes/proteins, and that UL28, gB and/or p40 proteins may effect the pathogenicity of HSV1.


Subject(s)
Genetic Complementation Test , Herpesvirus 1, Cercopithecine/genetics , Viral Envelope Proteins/genetics , 3T3 Cells , Animals , Chlorocebus aethiops , Genome, Viral , Herpesvirus 1, Cercopithecine/physiology , Herpesvirus 1, Human/genetics , Herpesvirus 1, Human/pathogenicity , Herpesvirus 1, Human/physiology , Mice , Recombination, Genetic , Vero Cells , Viral Plaque Assay , Virus Replication/genetics
17.
Curr Opin Rheumatol ; 9(6): 513-9, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9375280

ABSTRACT

A polymyositis syndrome has been described as a rare complication in patients who develop chronic graft-versus-host disease after allogeneic bone marrow transplantation. Chronic graft-versus-host disease is a cellular immune-mediated donor bone marrow versus patient rejection reaction, which may also lead to an autoimmune pathologic process. Chronic graft-versus-host disease-related polymyositis appears to be very similar to idiopathic myositis in its clinicopathologic presentation; chronic graft-versus-host disease-related myositis responds well to prednisone but cyclosporine may be an important component of second-line therapy due to its efficacy in controlling underlying chronic graft-versus-host disease.


Subject(s)
Graft vs Host Disease/complications , Myositis/etiology , Bone Marrow Transplantation/adverse effects , Diagnosis, Differential , Graft vs Host Disease/diagnosis , Graft vs Host Disease/drug therapy , Humans , Myositis/diagnosis , Myositis/drug therapy
18.
Cancer ; 78(9): 1899-905, 1996 Nov 01.
Article in English | MEDLINE | ID: mdl-8909309

ABSTRACT

BACKGROUND: Peripheral nerve toxicity has been reported but is not a commonly recognized complication of high dose cytosine arabinoside (HDAC) therapy. This study was undertaken to estimate the prevalence and describe the clinical spectrum of acute polyneuropathy associated with HDAC therapy for leukemia. METHODS: Records of 153 acute leukemia patients who received 194 courses of HDAC at the City of Hope were reviewed for evidence of severe peripheral neuropathy with onset 2-3 weeks after HDAC therapy. RESULTS: Two patients were identified who developed motor disability 2-3 weeks after HDAC therapy, and the disability progressed in a monophasic course to quadriparesis. There was neurophysiologic evidence of peripheral nerve demyelination with slowed nerve conduction velocities and conduction block. One patient who was autopsied had demyelination identified in luxol-fast blue sections of peripheral nerve (with Bielschowsky-stained sections showing intact peripheral nerve axons). There were foamy macrophages in the peripheral nerve but no chronic inflammatory cells. For comparison, data from these two patients were combined with those from four published case reports of polyneuropathy associated with HDAC therapy. Quadriparesis occurred in five of six cases with the need for ventilatory support in four. Cerebrospinal fluid protein was elevated in five of six cases. Etiologic evidence incriminating HDAC included simultaneous cerebellar signs in two of six cases and a narrow interval of clinical onset after HDAC therapy. CONCLUSIONS: Demyelinating polyneuropathy occurs in approximately 1% of HDAC courses and produces severe motor disability. HDAC immunosuppression could trigger an immune-mediated neuropathy; alternatively, a direct neurotoxic effect of HDAC on Schwann cells is also an etiologic possibility.


Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Cerebellar Diseases/chemically induced , Cytarabine/adverse effects , Demyelinating Diseases/chemically induced , Leukemia/drug therapy , Peripheral Nervous System Diseases/chemically induced , Acute Disease , Adult , Antimetabolites, Antineoplastic/administration & dosage , Cytarabine/administration & dosage , Female , Humans , Male , Middle Aged , Retrospective Studies
19.
Medicine (Baltimore) ; 75(5): 279-85, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8862349

ABSTRACT

A syndrome indistinguishable from idiopathic polymyositis occurred in 11 patients as a manifestation of chronic GVHD. All patients had elevation of creatine phosphokinase (CPK). Immunohistology demonstrated the effector cells in the muscle infiltrates as cytotoxic T cells, a finding similar to idiopathic polymyositis. Polymyositis is a rarely reported complication of chronic graft-versus-host disease (GVHD) with only 8 cases described in the literature. We encountered this syndrome in a small but significant percentage of our patients with chronic GVHD. Polymyositis associated with chronic GVHD does not affect the overall prognosis for the patient. Moreover, polymyositis can be the only manifestation of chronic GVHD. Awareness of this complication is important because it can be confused with other causes of muscle weakness after bone marrow transplantation. Finally, prompt initiation of corticosteroid therapy results in a rapid improvement of the associated symptoms.


Subject(s)
Bone Marrow Transplantation/adverse effects , Graft vs Host Disease/diagnosis , Polymyositis/diagnosis , Adolescent , Adult , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal , Child , Child, Preschool , Chronic Disease , Diagnosis, Differential , Female , Graft vs Host Disease/drug therapy , Graft vs Host Disease/etiology , Humans , Infant , Male , Middle Aged , Prednisone/administration & dosage , Prednisone/therapeutic use , Retrospective Studies
20.
Arch Virol ; 141(6): 1153-65, 1996.
Article in English | MEDLINE | ID: mdl-8712932

ABSTRACT

A recombinant vaccinia virus designated VgBt which expresses a truncated secreted herpes simplex virus gB (gBt) was constructed and compared to V11gB, a vaccinia recombinant previously studied which expresses gB exclusively on the surface of infected cells. Indirect immunofluorescence assay (IFA) revealed that gBt was strongly associated with the surface of infected cells despite being released slowly into the cell culture medium. Both gB and gBt existed as oligomers, and both membrane bound and secreted forms of gBt exhibited heparin-binding activity. In protection studies VgBt and V11gB conferred equivalent protection against both homologous (HSV-1) and heterologous (HSV-2) challenge with HSV.


Subject(s)
Heparin/metabolism , Herpes Simplex/prevention & control , Herpesvirus 1, Human/immunology , Viral Envelope Proteins/immunology , Viral Vaccines/immunology , Animals , Antigens, Viral/genetics , Antigens, Viral/immunology , Antigens, Viral/metabolism , Disease Models, Animal , Female , Herpes Simplex/immunology , Herpesvirus 1, Human/genetics , Humans , Mice , Mice, Inbred BALB C , Sequence Deletion , Structure-Activity Relationship , Vaccination , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Synthetic/metabolism , Vaccinia virus/genetics , Vaccinia virus/immunology , Viral Envelope Proteins/genetics , Viral Envelope Proteins/metabolism , Viral Vaccines/genetics , Viral Vaccines/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...